Cantor Fitzgerald Reiterates Neutral Rating on Alnylam Pharmaceuticals (ALNY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 158.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $158.00 | 52 Week High | $109.10 | |||
| Open | $158.00 | 52 Week Low | $31.38 | |||
| Day High | $158.00 | P/E | N/A | |||
| Day Low | $158.00 | EPS | $-1.45 | |||
| Volume | 137,757 | |||||
